Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2016-08-30 Regulatory Filings
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
NeuroVive announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in October 2016
Regulatory Filings Classification · 1% confidence The document is a short press release announcing that data from a clinical study (CiPRICS) will be presented at an external medical conference (Swedish Thorax meeting) in October 2016. It contains company boilerplate information and concludes with a statement that the information is made public pursuant to the EU Market Abuse Regulation. Since this is an announcement about an upcoming presentation of study data, and not the full financial report (10-K, IR), earnings release (ER), or a formal regulatory filing detailing a transaction or change in management, it best fits the general category for miscellaneous regulatory announcements or news releases that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement that isn't a specific financial report or management change.
2016-08-30 English
NeuroVives operative chef Jan Nilsson lämnar bolaget
Board/Management Information Classification · 1% confidence The document announces the departure of the Chief Operating Officer (COO), Jan Nilsson, from NeuroVive Pharmaceutical AB. It includes quotes from the departing COO and the Chairman of the Board, explaining the organizational restructuring that led to the position being eliminated. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information'. The document is a formal press release dated August 24, 2016, and concludes with a statement about information disclosure obligations under EU market abuse regulation, confirming its nature as a corporate announcement, not a full financial report or transcript.
2016-08-24 Swedish
NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company
Board/Management Information Classification · 1% confidence The document explicitly announces the departure of the Chief Operating Officer (COO), Jan Nilsson. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information'. The filing type code for this is MANG.
2016-08-24 English
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-June 2016. It contains detailed financial information, including income statements, earnings per share, and management commentary on business operations, research projects, and future outlook. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2016
2016-08-18 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report January - June 2016' and contains detailed financial information, including income statements, earnings per share, and management commentary on business operations for the specified period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2016
2016-08-18 English
NeuroVive fullföljer 10 procents delförvärv av Isomerase Therapeutics
Capital/Financing Update Classification · 1% confidence The document announces that NeuroVive has completed the second part of a previously announced partial acquisition (delförvärv) of Isomerase Therapeutics, resulting in NeuroVive owning approximately 10% of Isomerase shares. This transaction involves capital structure changes (acquiring shares via cash and previous share exchange) and is a specific corporate action announcement. It is not a standard periodic report (10-K, IR, ER) or a general regulatory filing (RNS). It directly relates to financing activities and capital structure adjustments, fitting best under 'Capital/Financing Update' (CAP). The document is a press release detailing a transaction, not a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), as it concerns the company's own investment activity.
2016-08-15 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.